FI107151B - Menetelmä uusien terapeuttisesti käyttökelpoisten 2-[4-(4,4-bis(4-fluorifenyyli)butyyli)piperatsin-1-yyli]pyridin-3-yyli-karboksyyliestrereiden valmistamiseksi - Google Patents

Menetelmä uusien terapeuttisesti käyttökelpoisten 2-[4-(4,4-bis(4-fluorifenyyli)butyyli)piperatsin-1-yyli]pyridin-3-yyli-karboksyyliestrereiden valmistamiseksi Download PDF

Info

Publication number
FI107151B
FI107151B FI946085A FI946085A FI107151B FI 107151 B FI107151 B FI 107151B FI 946085 A FI946085 A FI 946085A FI 946085 A FI946085 A FI 946085A FI 107151 B FI107151 B FI 107151B
Authority
FI
Finland
Prior art keywords
formula
compound
prepared
butyl
carbon atoms
Prior art date
Application number
FI946085A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI946085A (fi
FI946085A0 (fi
Inventor
Curt Nordvi
Gunnar Andersson
Goeran Pettersson
Anders Bjoerk
Torbjoern Lundstedt
Lisbeth Abramo
Wu Jin Chang
Catarina Ludwig
Elisabeth Seifert
Arne Nilsson
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of FI946085A publication Critical patent/FI946085A/fi
Publication of FI946085A0 publication Critical patent/FI946085A0/fi
Application granted granted Critical
Publication of FI107151B publication Critical patent/FI107151B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
FI946085A 1992-06-25 1994-12-23 Menetelmä uusien terapeuttisesti käyttökelpoisten 2-[4-(4,4-bis(4-fluorifenyyli)butyyli)piperatsin-1-yyli]pyridin-3-yyli-karboksyyliestrereiden valmistamiseksi FI107151B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE9201956A SE9201956D0 (sv) 1992-06-25 1992-06-25 Novel nicotinicacid esters
SE9201956 1992-06-25
SE9300565 1993-02-22
PCT/SE1993/000565 WO1994000434A1 (en) 1992-06-25 1993-06-23 Novel nicotinic acid esters

Publications (3)

Publication Number Publication Date
FI946085A FI946085A (fi) 1994-12-23
FI946085A0 FI946085A0 (fi) 1994-12-23
FI107151B true FI107151B (fi) 2001-06-15

Family

ID=20386602

Family Applications (1)

Application Number Title Priority Date Filing Date
FI946085A FI107151B (fi) 1992-06-25 1994-12-23 Menetelmä uusien terapeuttisesti käyttökelpoisten 2-[4-(4,4-bis(4-fluorifenyyli)butyyli)piperatsin-1-yyli]pyridin-3-yyli-karboksyyliestrereiden valmistamiseksi

Country Status (27)

Country Link
US (1) US5658910A (xx)
EP (2) EP0673368B1 (xx)
JP (1) JP3306827B2 (xx)
KR (1) KR100302216B1 (xx)
CN (1) CN1085981C (xx)
AT (2) ATE209634T1 (xx)
AU (1) AU681346B2 (xx)
BG (1) BG62000B1 (xx)
CA (1) CA2139112C (xx)
CZ (1) CZ281975B6 (xx)
DE (2) DE69331234T2 (xx)
DK (1) DK0673368T3 (xx)
EE (1) EE03122B1 (xx)
ES (1) ES2169044T3 (xx)
FI (1) FI107151B (xx)
HU (2) HU220613B1 (xx)
IL (1) IL106135A (xx)
NO (1) NO302945B1 (xx)
NZ (1) NZ253823A (xx)
PH (1) PH31417A (xx)
PT (1) PT673368E (xx)
RO (1) RO115725B1 (xx)
RU (1) RU2127732C1 (xx)
SE (1) SE9201956D0 (xx)
SK (1) SK279393B6 (xx)
WO (1) WO1994000434A1 (xx)
ZA (1) ZA934596B (xx)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632823B1 (en) * 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
DE69919707T2 (de) 1998-06-19 2005-09-01 Chiron Corp., Emeryville Glycogen synthase kinase 3 inhibitoren
US7045519B2 (en) * 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
BR112020022790A2 (pt) * 2018-05-09 2021-02-02 Lg Chem, Ltd novo composto que exibe atividade inibitória de enteropeptidase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8701375D0 (sv) * 1987-04-02 1987-04-02 Leo Ab Novel pyridyl- and pyrimidyl derivatives
SE9201239D0 (sv) * 1992-04-21 1992-04-21 Kabi Pharmacia Ab Agents for treating substance abuse disorders
SE9202265D0 (sv) * 1992-07-31 1992-07-31 Kabi Pharmacia Ab Novel- pyridyl and pyrimidylpiperazine derivatives

Also Published As

Publication number Publication date
ATE209634T1 (de) 2001-12-15
ES2169044T3 (es) 2002-07-01
NO945022D0 (no) 1994-12-23
US5658910A (en) 1997-08-19
KR100302216B1 (ko) 2001-11-22
WO1994000434A1 (en) 1994-01-06
EE03122B1 (et) 1998-10-15
NO302945B1 (no) 1998-05-11
ATE278671T1 (de) 2004-10-15
NZ253823A (en) 1996-01-26
FI946085A (fi) 1994-12-23
EP1120410A1 (en) 2001-08-01
IL106135A (en) 1999-01-26
DK0673368T3 (da) 2002-03-18
RO115725B1 (ro) 2000-05-30
EP1120410B1 (en) 2004-10-06
CZ281975B6 (cs) 1997-04-16
EP0673368B1 (en) 2001-11-28
SK279393B6 (sk) 1998-11-04
PH31417A (en) 1998-10-29
CA2139112A1 (en) 1994-01-06
HU220613B1 (hu) 2002-03-28
BG99289A (bg) 1995-09-29
CN1085981C (zh) 2002-06-05
PT673368E (pt) 2002-05-31
FI946085A0 (fi) 1994-12-23
AU4519393A (en) 1994-01-24
IL106135A0 (en) 1993-10-20
CZ327494A3 (en) 1995-09-13
JPH07508517A (ja) 1995-09-21
SE9201956D0 (sv) 1992-06-25
JP3306827B2 (ja) 2002-07-24
HU9403786D0 (en) 1995-02-28
CA2139112C (en) 2006-03-21
HUT71406A (en) 1995-11-28
CN1086811A (zh) 1994-05-18
BG62000B1 (bg) 1998-12-30
DE69331234D1 (de) 2002-01-10
SK158594A3 (en) 1995-07-11
AU681346B2 (en) 1997-08-28
RU94046310A (ru) 1996-10-27
ZA934596B (en) 1994-02-14
DE69331234T2 (de) 2002-08-08
DE69333655D1 (de) 2004-11-11
RU2127732C1 (ru) 1999-03-20
EP0673368A1 (en) 1995-09-27
HU210875A9 (en) 1995-08-28
NO945022L (no) 1995-02-13
KR950702186A (ko) 1995-06-19

Similar Documents

Publication Publication Date Title
KR100885104B1 (ko) 아자비시클릭 유도체, 이의 제조 방법 및 이를 함유하는약제 조성물
HU211256A9 (en) New benzimidazolone derivatives
FI107151B (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten 2-[4-(4,4-bis(4-fluorifenyyli)butyyli)piperatsin-1-yyli]pyridin-3-yyli-karboksyyliestrereiden valmistamiseksi
FI88300C (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara diazinylpiperidinderivat av cykliska amider och imider
NO174667B (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive pyridyl- og pyrimidylderivater
US4826843A (en) Cerebral function enhancing diazinylpiperidine derivatives
US6326371B1 (en) Pyrudyl and pyrimidylpiperazine derivatives
EP3986903B1 (en) Biaryl dialkyl phosphine oxide fpr2 agonists
US6441175B1 (en) 1-(N'-arylalkylaminoalkyl)aminoisoquinolines: a new class of dopamine receptor subtype
US5439940A (en) Benz[e]indene derivatives
KR100226328B1 (ko) 4-(4-또는6-(트리플루오로메틸-2-피리디닐))-1-피페라지닐알킬치환된락탐
US6313141B1 (en) 2-aminoalkylaminoquinolines as dopamine D4 ligands
US6613901B2 (en) 2-aminoalkylaminoquinolines as dopamine D4 ligands
JP2003342175A (ja) 新規なベンゾアゼピン誘導体又はその塩を有効成分とするメニエール病治療剤
MXPA06009346A (en) Novel azabicyclic derivatives, preparation method thereof and pharmaceutical compositions containing same
JPH04352721A (ja) 神経成長因子産生促進作用剤